Management of Acute Severe Asthma - Comprehensive MD Exam Answer (15 Marks)

Definition and Classification (GINA 2025)

Risk Factors for Death from Asthma (GINA)

• Previous near-fatal asthma requiring intubation
• Hospitalization or ED visit in the past year
• Currently using or recently stopped oral corticosteroids (OCS)
• Not currently using inhaled corticosteroids (ICS)
• Over-reliance on SABA (>1 canister/month)
• Low socioeconomic status, illicit drug use, psychiatric illness
• Denial of severity of illness

Clinical Features

• Dyspnea, inability to complete sentences
• Tachycardia, tachypnea
• Wheeze, chest hyperinflation
• Accessory muscle use, diaphoresis
• Pulsus paradoxus (>10 mmHg drop in SBP on inspiration)
• Fall in PEF

• Silent chest (minimal air entry - ominous)
• Bradycardia, hypotension
• Cyanosis
• Confusion, agitation, exhaustion (hypoxemia + hypercapnia)
• Bradypnea (= hypercarbia, impending arrest)
• SpO2 <92%, PaO2 <60 mmHg
• Normal or rising PaCO2 (loss of compensatory hyperventilation = impending respiratory failure)

Investigations

GINA 2025 Management Protocol

Initial Assessment and Monitoring (First 10-20 minutes)

• Assess severity (PEF, SpO2, RR, HR, consciousness level)
• Continuous pulse oximetry
• Vascular access; position upright
• Identify life-threatening features immediately

1. OXYGEN THERAPY - Immediate Priority

• Target SpO2: 94-98% (GINA 2025 - not high-flow titrated oxygen unless SpO2 <94%)
• Deliver by face mask or nasal cannula
• Hypoxemia is the primary cause of death in acute asthma - continuous SpO2 monitoring is mandatory
• GINA 2025 note: account for effect of skin color and altitude when interpreting SpO2

2. INHALED SHORT-ACTING BETA-2 AGONISTS (SABA) - First-Line Bronchodilator

• Nebulizer (O2-driven): 2.5-5 mg every 20 minutes for first hour (3 doses back-to-back in severe exacerbation), then reassess
• pMDI with spacer (equally effective): 4-8 puffs every 20 minutes for 3 doses, then every 1-4 hours
• Continuous nebulization may be used in very severe/refractory cases

3. IPRATROPIUM BROMIDE - Add-on Anticholinergic

• Indication: Moderate to severe exacerbations (PEF <40% predicted)
• Mechanism: Blocks parasympathetic bronchoconstriction; does not cause tachycardia
• Dose: 0.5 mg nebulized with the first 3 albuterol treatments (every 20 minutes x 3); equivalent MDI dose = 8 puffs (18 mcg/puff) every 20 minutes x 3 doses
• Onset: 30-120 minutes; duration: up to 6 hours
• Evidence (GINA - Evidence A for adults): Combined SABA + ipratropium associated with fewer hospitalizations and greater improvement in PEF compared to SABA alone
• No role for tiotropium (long-acting) in acute exacerbations
• Note: ipratropium should NOT be used as monotherapy in acute attacks

4. SYSTEMIC CORTICOSTEROIDS - Anti-inflammatory Cornerstone

• Oral: Prednisolone 40-50 mg once daily (equally effective as IV if patient can swallow)
• IV (if can't swallow): Methylprednisolone 125 mg IV OR hydrocortisone 100-200 mg IV

5. MAGNESIUM SULFATE - Second-Line Agent (GINA 2025)

• Acute severe asthma FEV1/PEF <25-30% predicted
• No initial good response to inhaled bronchodilators
• Life-threatening features
• Adults and children with persistent hypoxia after initial treatment
• Children with PEF <60% after 1 hour of treatment

Recent Evidence (2025): A systematic review in Archives of Disease in Childhood (PMID: 40562459, 2025) confirmed IV magnesium sulfate as a beneficial second-line agent in acute severe asthma exacerbations in children when added to standard first-line treatment with SABA and systemic steroids.

6. AMINOPHYLLINE/THEOPHYLLINE - Third-Line (Limited Role)

• GINA position: Not recommended routinely - risks of toxicity far outweigh benefits when inhaled beta-2 agonists are available
• Limited role in near-fatal asthma with poor response to initial therapy when other agents have failed
• Dose: IV aminophylline loading dose 5 mg/kg over 20-30 minutes (omit if already on theophylline - measure level first); maintenance 0.5 mg/kg/hour
• Serious toxicities: Arrhythmias, seizures, narrow therapeutic index (10-20 mcg/mL)
• Contraindication: Do not give without checking serum theophylline level if on oral theophylline

7. NONINVASIVE POSITIVE PRESSURE VENTILATION (NIPPV/NIV)

• Benefit: Improves airflow and respirations, reduces work of breathing, can temporize while pharmacotherapy takes effect
• Role: Bridge therapy before intubation in deteriorating patients
• Forms: BiPAP (bilevel positive airway pressure) preferred in acute asthma
• Reduces intubation rates in selected patients; not universally effective
• Contraindications: Severely altered consciousness, inability to protect airway, hemodynamic instability

Indications for ICU Admission and Intubation

• Acute severe/life-threatening asthma failing to respond to therapy
• Deteriorating PEF
• Worsening or persistent hypoxemia
• Normal or rising PaCO2 (indicates ventilatory failure)
• Poor respiratory effort, exhaustion, or confusion
• Silent chest, bradycardia, or hypotension

• Respiratory arrest
• Cardiac arrest
• Deteriorating consciousness despite maximal therapy
• Worsening hypoxemia/hypercapnia despite NIV

Mechanical Ventilation Strategy

• Low respiratory rate: 8-12 breaths/min (maximize expiratory time to allow air to exit)
• Low tidal volumes: 6-8 mL/kg IBW
• Prolonged expiratory time (I:E ratio 1:3 to 1:5)
• Permissive hypercapnia: Accept PaCO2 up to 80-100 mmHg to avoid barotrauma; gradually increase PaCO2 by ~10% per hour; provide bicarbonate buffering if pH <7.20
• Low or zero PEEP initially (auto-PEEP already high)
• Monitor peak and plateau inspiratory pressures; aim plateau <30 cmH2O
• Avoid over-sedation but use adequate sedation and analgesia (morphine may trigger histamine release - use fentanyl)
• Sedatives are NEVER to be given without ventilatory support as they depress respiration

Additional/Emerging Therapies (Recent Advances)

1. Heliox (Helium-Oxygen Mixture)

• 60-80% helium blended with 20-40% oxygen
• 3-fold reduction in gas density vs air - promotes laminar flow in obstructed airways, reducing resistance
• Benefit lost when mixture contains <70% helium (so limited utility in patients who need high FiO2)
• Can be used to drive nebulized bronchodilators in non-responding patients
• Evidence: mixed clinical results; not a standard recommendation but useful adjunct in refractory cases

2. Ketamine

• Dissociative anesthetic with bronchodilatory properties (sympathomimetic, inhibits smooth muscle contraction)
• Used for procedural sedation before intubation and as adjunct IV infusion
• Dose: 1-2 mg/kg IV for induction; 0.1-0.5 mg/kg/hour for maintenance
• Preferred induction agent for intubation in severe asthma

3. Inhalational Anesthetics (Isoflurane, Sevoflurane)

• Potent bronchodilators; reserved for refractory status asthmaticus in ICU
• Requires specialized delivery equipment (AnaConDa or similar)
• Limited to tertiary centers

4. ECMO (Extracorporeal Membrane Oxygenation)

• Indication: Near-fatal asthma refractory to mechanical ventilation
• VV-ECMO (venovenous) for respiratory failure
• Registry data and case reports support a role - no formal RCT evidence
• Allows "rest" of the lungs while bronchospasm resolves
• Relevant only in tertiary/quaternary centers with ECMO capability
• Rosen's Emergency Medicine: "ECMO may be indicated for severe asthma refractory to conventional therapies"

5. GINA 2025 - ICS-Formoterol MART (Maintenance and Reliever Therapy)

• The preferred approach for step 1-4 outpatient management; reduces severe exacerbation risk vs SABA-based regimens
• In discharge planning after severe exacerbation: all patients should be prescribed ongoing ICS-containing treatment; preferred regimen = maintenance-and-reliever therapy (MART) with ICS-formoterol
• ICS-formoterol reduces severe exacerbations significantly compared to SABA relievers

6. Type 2 Biomarkers (GINA 2025 - New Appendix)

• Blood eosinophil count (BEC) and FeNO (fractional exhaled nitric oxide) newly expanded in GINA 2025
• High BEC = at or above upper limit of normal for population
• Guides add-on biologic therapy decisions in severe asthma
• Relevant to post-exacerbation phenotyping

Drugs NOT to Use

Discharge Planning (GINA 2025)

• Prescribe oral prednisolone course (40-50 mg/day x 5-7 days)
• Prescribe ICS-containing inhaler (or ensure already on one)
• Check and correct inhaler technique
• Provide written asthma action plan
• Follow-up within 2-7 days (1-2 days for children)
• Identify and address triggers

Summary Algorithm (GINA 2025 ED Management)

PRESENTATION → Assess severity (PEF, SpO2, HR, RR, consciousness)
      ↓
IMMEDIATE:  O2 (target SpO2 94-98%)
            SABA (salbutamol) every 20 min x 3 doses
            Ipratropium 0.5 mg (moderate-severe) every 20 min x 3
            Systemic corticosteroids (oral prednisolone 40-50 mg OR IV methylprednisolone)
      ↓
REASSESS after 1 hour
      ↓
NO RESPONSE / LIFE-THREATENING:
            IV Magnesium sulfate 2 g over 20-30 min
            Consider NIV (BiPAP)
            ICU referral
      ↓
REFRACTORY:
            Consider heliox, ketamine
            Intubation + mechanical ventilation (permissive hypercapnia strategy)
            Consider inhalational anesthetics / ECMO (tertiary center)

Key GINA 2025 Updates to Remember for Exams

1. Nebulized magnesium is no longer recommended (removed 2025)
2. IV magnesium remains a key second-line agent in severe/life-threatening cases
3. SABA doses have been clarified to avoid excessive use
4. SpO2 target remains ≥94% (not 94-98% upper limit strictly enforced)
5. Preferred post-discharge regimen = ICS-formoterol MART
6. FeNO and blood eosinophils now have an expanded role as Type 2 biomarkers
7. Follow-up after exacerbation: 2-7 days for adults (1-2 days for children)